New Rx Antihistamines Free From Cardio Risks Of Predecessors - JAPhA
This article was originally published in The Tan Sheet
Executive Summary
Newer second-generation antihistamines are safer than older Rx drugs discontinued for safety reasons, a commentary in the May/June Journal of the American Pharmaceutical Association asserts.
You may also be interested in...
Antihistamine OTC Switch: FDA Asking If Rx Products Have "Unique" Aspects
FDA regards the safety profiles of Rx antihistamines Claritin, Allegra and Zyrtec to be at least as good as currently marketed OTC antihistamines, briefing documents for the upcoming May 11 advisory committee meeting indicate.
FDA Authority To Force Antihistamine Switch Denounced By Pfizer Chief
FDA lacks the statutory power to force a prescription antihistamine to switch OTC, Pfizer CEO Henry McKinnell insisted during an analysts call April 18.
Antihistamine OTC Switch Petition Slated For NDAC Debate May 11
FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.